GlassScriptPhysician profile
Katherine Miller
NPI 1306057609
$4,518.33
in general payments reported to CMS, 2019-2025
33 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,780 · 2020: $396 · 2021: $570 · 2022: $650 · 2023: $448 · 2024: $462 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $832.59 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Astrazeneca Pharmaceuticals LP | $668.73 | 2019-2022 | |
| Novo Nordisk INC | $426.30 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $323.29 | 2019-2025 | Zepbound, Mounjaro |
| Insulet Corporation | $294.57 | 2019-2023 | Omnipod |
| Amgen INC. | $187.76 | 2019-2023 | Evenity, Prolia |
| Tandem Diabetes Care, INC. | $172.50 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $167.32 | 2019-2023 | |
| Abbott Laboratories | $152.82 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Boston Scientific Corporation | $145.12 | 2024 | Wavewriter Alpha Prime 16 |
| Xeris Pharmaceuticals, INC. | $140.49 | 2022-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $126.45 | 2019-2020 | |
| Medtronic Minimed, INC. | $114.58 | 2019 | |
| Stryker Corporation | $106.90 | 2024 | Na, Scopis Ent |
| Merck Sharp & Dohme LLC | $84.55 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.76 | 2019-2023 | Synjardy, Jardiance |
| Valeritas, INC. | $67.09 | 2019 | |
| Amarin Pharma, INC. | $63.86 | 2019-2020 | |
| Shire North American Group INC | $56.85 | 2019 | |
| Vivus LLC | $33.49 | 2019 | |
| Evoke Pharma, INC. | $32.49 | 2024-2025 | |
| Corcept Therapeutics | $29.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.87 | 2019 | |
| Abbvie INC. | $29.46 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $27.36 | 2019 | |
| Embecta Corp. | $25.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Endo Pharmaceuticals INC. | $18.75 | 2019 | |
| Mannkind Corporation | $17.54 | 2019 | |
| Cequr Corporation | $15.63 | 2022 | |
| Pfizer INC. | $14.39 | 2024 | |
| Companion Medical, INC. | $12.32 | 2019 | |
| Currax Pharmaceuticals LLC | $11.98 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.